KETOROLAC TROMETHAMINE Drug Interactions

Clinical Management

The primary clinical effect is a substantially increased risk of serious bleeding, including gastrointestinal hemorrhage, peptic ulcers, and intracranial bleeding. The risk of major gastrointestinal bleeding can be several-fold higher compared to either drug alone, potentially leading to hospitalization, transfusions, or even death. This combination should be avoided if possible. If concomitant use is absolutely necessary, it should be done with extreme caution, close monitoring for signs of bleeding (e.g., black stools, easy bruising, unusual fatigue), and for the shortest duration possible. Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen. Proton pump inhibitor prophylaxis may be considered if unavoidable.

Clinical Management

Patients are at a substantially increased risk of bleeding, particularly gastrointestinal bleeding, which can manifest as black or tarry stools, vomiting blood, or severe abdominal pain. Other potential bleeding sites include the brain, urinary tract, and soft tissues. The risk of major bleeding can be several-fold higher compared to using either drug alone. This combination is generally contraindicated due to the high risk of severe bleeding. If an NSAID is absolutely necessary, consider alternatives with lower systemic absorption (e.g., topical NSAIDs for localized pain) or alternative pain management strategies. Close monitoring for signs of bleeding is essential if no alternative can be found, but this is strongly discouraged. Consult with a healthcare professional to explore safer pain relief options.

Clinical Management

The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, but also bleeding from other sites. This can manifest as blood in stools, dark tarry stools, vomiting blood, nosebleeds, or bruising. The risk of major bleeding can be several-fold higher compared to using either drug alone. This combination should generally be avoided due to the high risk of bleeding. If an NSAID is absolutely necessary, consider alternative pain management strategies or a short course of a COX-2 selective NSAID (e.g., celecoxib) with extreme caution and close monitoring, though even this carries significant risk. Patients must be educated on signs of bleeding and seek immediate medical attention if they occur.

Clinical Management

Patients are at a substantially increased risk of serious bleeding events, including gastrointestinal hemorrhage, intracranial hemorrhage, and other major bleeding. The risk of gastrointestinal bleeding alone can be several-fold higher compared to either drug alone, potentially leading to anemia, hypovolemic shock, or death. This combination should generally be avoided due to the high risk of severe bleeding. If concurrent use is unavoidable, patients require very close monitoring for signs of bleeding (e.g., melena, hematemesis, epistaxis, bruising, changes in vital signs, decreasing hemoglobin) and frequent coagulation parameter checks. Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen or opioids.

Clinical Management

The primary clinical effect is a substantially increased risk of bleeding, which can range from minor events like bruising or nosebleeds to severe and life-threatening hemorrhages, including gastrointestinal, intracranial, or retroperitoneal bleeding. The risk of major bleeding is significantly elevated compared to either agent alone. This combination is generally contraindicated due to the high risk of severe bleeding. If co-administration is unavoidable, extreme caution and close monitoring for signs of bleeding are essential. Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen or opioids. If NSAID use is absolutely necessary, use the lowest effective dose for the shortest duration possible and discontinue bivalirudin if clinically feasible.

Clinical Management

The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, which can be severe or fatal. Studies indicate that the risk of major gastrointestinal bleeding is 3 to 15 times higher when NSAIDs are co-administered with warfarin. Other potential bleeding sites include intracranial, genitourinary, and soft tissue. This combination is generally contraindicated due to the high risk of severe bleeding. If concurrent use is unavoidable, extreme caution, close monitoring of INR and signs of bleeding, and the lowest effective dose of ketorolac for the shortest duration are essential. Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen or opioids, if appropriate.

Clinical Management

The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding (e.g., ulcers, hemorrhage), but also epistaxis, hematuria, and bruising. Studies show that combining NSAIDs with DOACs can increase the risk of major bleeding by 2-3 fold compared to DOACs alone, with GI bleeding being the most common and serious manifestation. This combination should be avoided due to the high risk of serious bleeding. If an NSAID is absolutely necessary, consider alternative analgesics such as acetaminophen. If no alternative is feasible and the NSAID is short-term, close monitoring for signs of bleeding (e.g., black stools, easy bruising, unusual fatigue) is crucial, and the lowest effective dose for the shortest duration should be used. Proton pump inhibitor co-therapy may reduce GI bleeding risk but does not eliminate it.

Clinical Management

The primary clinical effect is a substantially elevated risk of bleeding, including gastrointestinal bleeding, intracranial hemorrhage, and other major bleeding events. Studies show that combining NSAIDs with DOACs can increase the risk of major bleeding by 2-3 fold compared to DOAC monotherapy, with a particularly high risk of upper gastrointestinal bleeding. This combination should generally be avoided due to the high bleeding risk. If pain management is necessary, consider alternative analgesics such as acetaminophen. If an NSAID is absolutely required, use the lowest effective dose for the shortest duration possible, and monitor closely for signs of bleeding. Proton pump inhibitor co-therapy may be considered to reduce GI bleeding risk.

Clinical Management

The primary clinical effect is a substantially increased risk of serious bleeding, such as gastrointestinal hemorrhage, intracranial hemorrhage, or other major bleeding events. This risk is dose-dependent and can be life-threatening. Studies indicate that concurrent use of NSAIDs and anticoagulants can increase the risk of GI bleeding by 3 to 15 times compared to anticoagulants alone. This combination should be avoided whenever possible. If both agents are absolutely necessary, extremely close monitoring for signs of bleeding (e.g., melena, hematemesis, petechiae, bruising, altered mental status) is mandatory. Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen or opioids. If an NSAID is required, a COX-2 selective inhibitor might be considered with extreme caution, but ketorolac is non-selective and carries high risk.

Clinical Management

The primary clinical effect is a substantially increased risk of bleeding, which can be severe or even fatal. This includes gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and bleeding from other sites. The risk of major bleeding can be several-fold higher compared to either drug alone. This combination should be avoided due to the high risk of serious bleeding. If pain management is required, consider alternative analgesics such as acetaminophen or opioids, carefully weighing the risks and benefits. Close monitoring for signs of bleeding (e.g., black stools, easy bruising, unusual bleeding) is crucial if co-administration is unavoidable, but generally, an alternative pain management strategy is preferred.

Clinical Management

The primary clinical effect is a substantially increased risk of bleeding, which can be severe or life-threatening. This includes gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other forms of internal bleeding. The risk of major bleeding can be several-fold higher compared to monotherapy. This combination is generally contraindicated due to the high risk of severe bleeding. If an NSAID is absolutely necessary, consider alternatives with lower GI risk (e.g., celecoxib if cardiac risk allows) or topical NSAIDs, but even then, close monitoring for bleeding is essential. If fondaparinux cannot be interrupted, alternative pain management strategies that do not increase bleeding risk should be used.

Clinical Management

This interaction substantially increases the risk of serious bleeding events, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other systemic bleeding. The risk of GI bleeding with NSAIDs alone is 2-4 times higher, and combining with antiplatelets further elevates this risk significantly. This combination should generally be avoided due to the high risk of bleeding. If concurrent therapy is absolutely necessary, use the lowest effective doses for the shortest duration possible, and monitor closely for signs of bleeding (e.g., black tarry stools, easy bruising, nosebleeds). Consider alternative pain management strategies or antiplatelet agents if appropriate.

Clinical Management

This combination carries a high risk of severe bleeding, including gastrointestinal hemorrhage, intracranial hemorrhage, and other major bleeding events. Patients may experience symptoms like black, tarry stools, vomiting blood, unusual bruising, or prolonged bleeding from cuts. The absolute risk of major bleeding can be substantially elevated, potentially exceeding 2-3 times compared to ticagrelor alone. Concomitant use of ketorolac and ticagrelor should generally be avoided due to the high risk of major bleeding. If an NSAID is absolutely necessary, consider alternatives with lower GI risk, such as celecoxib, and use for the shortest duration possible, while closely monitoring for signs of bleeding. Proton pump inhibitor (PPI) co-therapy is recommended if an NSAID must be used. Consider alternative pain management strategies that do not affect platelet function.

Clinical Management

The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding (e.g., ulcers, hemorrhage), but also bleeding from other sites. Studies indicate that the risk of major bleeding can be 3 to 15 times higher when NSAIDs are combined with antiplatelets compared to antiplatelets alone, with a specific concern for upper gastrointestinal bleeding. Symptoms may include black, tarry stools, vomiting blood, or unusual bruising. This combination should generally be avoided due to the high risk of serious bleeding. If an NSAID is absolutely necessary, consider alternative pain management strategies or a COX-2 selective NSAID (like celecoxib) for the shortest duration possible, though even these carry increased risk. Closely monitor for any signs of bleeding (e.g., melena, hematemesis, petechiae, unexplained bruising). Proton pump inhibitors (PPIs) may be co-prescribed to reduce gastrointestinal bleeding risk if the combination is unavoidable, but this does not eliminate the risk.

Clinical Management

The primary clinical effect is a substantially increased risk of bleeding, including gastrointestinal bleeding, intracranial hemorrhage, and other serious bleeding events. Studies show a significantly elevated risk of major bleeding when NSAIDs are co-administered with antiplatelet agents, potentially increasing the risk by 2 to 4 times compared to antiplatelet monotherapy. This combination should generally be avoided due to the high risk of bleeding. If an NSAID is absolutely necessary, consider a COX-2 selective inhibitor for the shortest duration possible, but even then, close monitoring for bleeding is essential. Alternative pain management strategies that do not increase bleeding risk, such as acetaminophen or opioids, should be prioritized. Patients must be educated on signs of bleeding.

Clinical Management

Patients are at a substantially increased risk of serious bleeding events, including gastrointestinal hemorrhage, intracranial hemorrhage, and other forms of major bleeding. The risk of GI bleeding with NSAIDs alone can be significant, and this risk is amplified when combined with antiplatelet agents like cilostazol. This combination should generally be avoided due to the high risk of bleeding. If an NSAID is absolutely necessary, consider alternative analgesics or use a gastroprotective agent (e.g., proton pump inhibitor) and monitor closely for signs of bleeding. Consider alternative antiplatelet agents or adjust cilostazol dosage under strict medical supervision if no other option is available.